The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Paul Kellam, Wendy Barclay, Paul Kellam, Wendy Barclay

Abstract

SARS-CoV-2 is a novel coronavirus that is the causative agent of coronavirus infectious disease 2019 (COVID-19). As of 17 April 2020, it has infected 2 114 269 people, resulting in 145 144 deaths. The timing, magnitude and longevity of humoral immunity is not yet understood for SARS-CoV-2. Nevertheless, understanding this is urgently required to inform the likely future dynamics of the pandemic, to guide strategies to allow relaxation of social distancing measures and to understand how to deploy limiting vaccine doses when they become available to achieve maximum impact. SARS-CoV-2 is the seventh human coronavirus to be described. Four human coronaviruses circulate seasonally and cause common colds. Two other coronaviruses, SARS and MERS, have crossed from animal sources into humans but have not become endemic. Here we review what is known about the human humoral immune response to epidemic SARS CoV and MERS CoV and to the seasonal, endemic coronaviruses. Then we summarize recent, mostly non-peer reviewed, studies into SARS-CoV-2 serology and reinfection in humans and non-human primates and summarize current pressing research needs.

Keywords: COVID-19; SARS-CoV-2; antibodies; reinfection; serology.

Conflict of interest statement

The authors have no conflicts of interests with respect to this review.

Figures

Fig. 1.
Fig. 1.
A schematic representation of the SARS-CoV-2 immune response following infection. Seroconversion occurs from approximately 10 days after symptom onset with the exact timing of IgM (green line) and IgG (red line; high titre, solid line; low titre, dashed line) appearance presently unclear, but with a suggestion that the IgM occurs at the time of, and overlapping with, the IgG response. The IgG antibody titres rise from day 10 onwards to reach a peak whose height is likely to be influenced, on a case by case basis, by disease severity and virus load. Seropositive status for those that seroconvert is detectable from 3 to 4 weeks from symptom onset. The level of antibody protection from reinfection (black dotted line), the duration of the total humoral immune response above this level, and the rate of decline from mild or severe infection induced antibodies is not known for SARS-CoV-2. Similarly, the proportion of infected individuals that do not mount a protective immune response (blue line) is not known.

References

    1. Choe PG, Perera RAPM, Park WB, Song K-H, Bang JH, et al. Mers-Cov antibody responses 1 year after symptom onset, South Korea, 2015. Emerg Infect Dis. 2017;23:1079–1084. doi: 10.3201/eid2307.170310.
    1. Alshukairi AN, Khalid I, Ahmed WA, Dada AM, Bayumi DT, et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Infect Dis. 2016;22 doi: 10.3201/eid2206.160010.
    1. Payne DC, Iblan I, Rha B, Alqasrawi S, Haddadin A, et al. Persistence of antibodies against middle East respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22:1824–1826. doi: 10.3201/eid2210.160706.
    1. Okba NMA, Raj VS, Widjaja I, GeurtsvanKessel CH, de Bruin E, et al. Sensitive and specific detection of low-level antibody responses in mild middle East respiratory syndrome coronavirus infections. Emerg Infect Dis. 2019;25:1868–1877. doi: 10.3201/eid2510.190051.
    1. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med. 2014;371:828–835. doi: 10.1056/NEJMoa1405858.
    1. Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007;357:1162–1163. doi: 10.1056/NEJMc070348.
    1. Mo H, Zeng G, Ren X, Li H, Ke C, et al. Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and their clinical significance. Respirology. 2006;11:49–53. doi: 10.1111/j.1440-1843.2006.00783.x.
    1. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13:1562–1564. doi: 10.3201/eid1310.070576.
    1. Liu W, Fontanet A, Zhang P-H, Zhan L, Xin Z-T, et al. Two-Year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006;193:792–795. doi: 10.1086/500469.
    1. Liu L, Xie J, Sun J, Han Y, Zhang C, et al. Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. Scand J Infect Dis. 2011;43:515–521. doi: 10.3109/00365548.2011.560184.
    1. Guo X, Guo Z, Duan C, chen Z, Wang G, et al. Long-Term persistence of IgG antibodies in SARS-CoV infected healthcare workers. medRxiv. 2020
    1. Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Müller MA, et al. Human coronavirus NL63 and 229E seroconversion in children. J Clin Microbiol. 2008;46:2368–2373. doi: 10.1128/JCM.00533-08.
    1. Gorse GJ, Donovan MM, Patel GB. Antibodies to coronaviruses are higher in older compared with younger adults and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus-associated illnesses. J Med Virol. 2020;92:512–517. doi: 10.1002/jmv.25715.
    1. Ambrosioni J, Bridevaux P-O, Wagner G, Mamin A, Kaiser L. Epidemiology of viral respiratory infections in a tertiary care centre in the era of molecular diagnosis, Geneva, Switzerland, 2011-2012. Clin Microbiol Infect. 2014;20:O578–O584. doi: 10.1111/1469-0691.12525.
    1. Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res. 2007;38:281–297. doi: 10.1051/vetres:2006055.
    1. Vijgen L, Keyaerts E, Lemey P, Moës E, Li S, et al. Circulation of genetically distinct contemporary human coronavirus OC43 strains. Virology. 2005;337:85–92. doi: 10.1016/j.virol.2005.04.010.
    1. Ren L, Zhang Y, Li J, Xiao Y, Zhang J, et al. Genetic drift of human coronavirus OC43 spike gene during adaptive evolution. Sci Rep. 2015;5:11451. doi: 10.1038/srep11451.
    1. Kiyuka PK, Agoti CN, Munywoki PK, Njeru R, Bett A, et al. Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya. J Infect Dis. 2018;217:1728–1739. doi: 10.1093/infdis/jiy098.
    1. Aldridge RW, Lewer D, Beale S, Johnson AM, Zambon M, et al. Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the flu watch cohort study. Wellcome Open Res. 2020;5:52. doi: 10.12688/wellcomeopenres.15812.1.
    1. Dijkman R, Jebbink MF, Gaunt E, Rossen JWA, Templeton KE, et al. The dominance of human coronavirus OC43 and NL63 infections in infants. J Clin Virol. 2012;53:135–139. doi: 10.1016/j.jcv.2011.11.011.
    1. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020:eabb5793. doi: 10.1126/science.abb5793.
    1. Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990;105:435–446. doi: 10.1017/S0950268800048019.
    1. Reed SE. The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers. J Med Virol. 1984;13:179–192.
    1. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, et al. Evaluation of nine commercial SARS-CoV-2 immunoassays. medRxiv. 2020
    1. Adams ER, Anand R, Andersson M, I, Auckland K, et al. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. medRxiv. 2020
    1. Whitman JD, Hiatt J, Mowery CT, Shy BR, Yu R, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv. 2020
    1. Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, et al. Performance characteristics of the Abbott architect SARS-CoV-2 IgG assay and seroprevalence testing in Idaho. medRxiv. 2020
    1. Lipsitch M, Kahn R, Mina MJ. Antibody testing will enhance the power and accuracy of COVID-19-prevention trials. Nat Med. 2020 doi: 10.1038/s41591-020-0887-3.
    1. Uttenthal A, Parida S, Rasmussen TB, Paton DJ, Haas B, et al. Strategies for differentiating infection in vaccinated animals (DIVA) for foot-and-mouth disease, classical swine fever and avian influenza. Expert Rev Vaccines. 2010;9:73–87. doi: 10.1586/erv.09.130.
    1. Zhao J, Yuan Q, Wang H, Liu W, Liao X, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa344.
    1. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020a;62 doi: 10.1038/s41591-020-0897-1.
    1. Lou B, Li T, Zheng S, Su Y, Li Z, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset. medRxiv. 2020
    1. Okba NMA, Muller MA, Li W, Wang C, GeurtsvanKessel CH, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv. 2020
    1. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;382 doi: 10.1038/s41586-020-2196-x.
    1. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26:453–455. doi: 10.1038/s41591-020-0819-2.
    1. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20:565–574. doi: 10.1016/S1473-3099(20)30196-1.
    1. Wu F, Wang A, Liu M, Wang Q, Chen J, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020
    1. Thompson C, Grayson N, Paton R, Lourenço J, Penman B, et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors - a pilot study of the value of serology to determine population exposure. medRxiv. 2020
    1. Quinlan BD, Mou H, Zhang L, Guo Y, He W, et al. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement. SSRN Journal. 2020 doi: 10.2139/ssrn.3575134.
    1. Chen H. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2. BioRxiv. 2020
    1. Kim Y-I, Kim S-G, Kim S-M, Kim E-H, Park S-J, et al. Infection and rapid transmission of SARS-CoV-2 in ferrets. Cell Host Microbe. 2020 doi: 10.1016/j.chom.2020.03.023.
    1. Munster V, Feldmann F, Williamson B, van Doremalen N, Perez-Perez L, et al. Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. BioRxiv. 2020
    1. Bao L, Deng W, Gao H, Xiao C, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. BioRxiv. 2020

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться